Palanisamy Chella Perumal
Karpagam University, India
Title: Computational and experimental investigations on bioactive compounds from Cayratia Trifolia l. targeting ovarian cancer
Biography
Biography: Palanisamy Chella Perumal
Abstract
Ovarian cancer is the sixth most frequent cause of cancer related death. HER2 and CXCR4 overexpression is implicated in the initiation and progression of ovarian cancer. Compounds from natural sources are preferred to conventional treatment methods, because of lesser side effects and improved treatment outcome. Cayratia trifolia (L.) has been reported to possess anticancer activities. To date, the bioactive compounds have not been isolated from this plant and tested against ovarian cancer. Therefore the present study was attempted to isolate the bioactive compounds to treat the ovarian cancer. Initially, chromatographic and spectroscopic methods were used to isolate and characterize the bioactive compounds from this plant extract. The computational methods and in vitro assay were used to examine the anti-ovarian cancer activity. The chromatographic and spectroscopic methods identified and confirmed the presence of Polyprenol and 12-(10-carboxydecanoyloxy) -12-oxododecanoic acid. This is the first study to report the presence of these compounds in Cayratia trifolia (L.). 12-(10-carboxydecanoyloxy)-12-oxododecanoic acid and Polyprenol have good inhibitory activity against HER2 and CXCR4 (Ovarian cancer target proteins) when compared with cyclophosphamide (FDA approved drug for cancer). The ADME properties prediction of these compounds was under acceptable range. In addition these compounds have admirable cell growth inhibitory activity at low concentrations as evidenced by the MTT assay in vitro (using A2780 cell line). These results conclude that, the 12-(10-carboxydecanoyloxy)-12-oxododecanoic acid and Polyprenol inhibits the cell survival through modulating HER2 and CXCR4. However further studies are warranted to substantiate the current findings